Welcome to our dedicated page for CORCEPT THERAPEUTICS SEC filings (Ticker: CORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.
The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.
Corcept Therapeutics (CORT) director reports option exercise and sale. On 10/10/2025, the reporting person exercised 2,200 stock options at $14.08 per share and sold 2,200 shares at $87.54, both reported as direct holdings. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 1, 2024.
Following these transactions, common stock directly held was 0 shares. The filer reports 1,100 derivative securities (stock options) remaining directly owned, which are fully exercisable and carry an expiration date of 08/20/2028.
Corcept Therapeutics (CORT) terminated its distribution services agreement with Optime Care, delivering notice on October 10, 2025, with termination effective January 8, 2026. Optime had served as a specialty pharmacy distributor for Korlym and Corcept’s authorized generic mifepristone, handling pharmacy operations, patient access, reimbursement support, claims, A/R, and reporting.
The agreement, originally dated August 4, 2017 and amended and restated April 1, 2024, had been extended through March 31, 2027 with automatic three-year renewals. Corcept previously informed Optime that, under its contractual rights, Optime’s exclusivity ended on September 15, 2025. The contract permitted termination for convenience by Corcept with 90-days advance notice, as well as customary remedies for material breach.
Corcept Therapeutics (CORT) reported a Form 144 notice for the proposed sale of 2,200 common shares with an aggregate market value of $192,588, scheduled for 10/10/2025 on NASDAQ. The filing states the shares were acquired under an option granted on 08/20/2018 and payment will be in cash. The filing also discloses three prior sales by the same seller: 2,200 shares on 07/10/2025 for $156,376, 2,200 shares on 08/11/2025 for $159,060, and 2,200 shares on 09/10/2025 for $159,390, totaling $474,826 in gross proceeds. Outstanding shares are listed as 105,371,729, making the scheduled sale a very small fraction of total shares outstanding.
Insider transactions by Chief Development Officer William Guyer show simultaneous option exercise and stock sales dated 10/07/2025. Mr. Guyer exercised 20,000 stock options at an exercise price of $21.65 per share, immediately acquiring 20,000 shares. The same day he sold 20,000 shares under a Rule 10b5-1 plan for a weighted average sale price of $89.9391 per share (range $89.85–$90.18). After these transactions his reported beneficial ownership is 25,287 shares of common stock and he holds 310,000 shares underlying outstanding options exercisable through 09/01/2031. The filing was signed by an attorney-in-fact on 10/09/2025.
Corcept Therapeutics Inc. reported a Rule 144 notice for the proposed sale of 20,000 common shares through Stifel Nicolaus & Company Inc. on 10/07/2025. The filing lists an aggregate market value of $1,797,000 and states 105,370,000 shares outstanding, indicating the transaction size relative to the company's issued stock. The shares were acquired the same day by stock option exercise and paid for in cash, according to the acquisition table.
The notice also discloses multiple sales by the same person, William Guyer, over the past three months: 4,379, 500, 14, 35,007, and 20,000 shares on dates from 07/17/2025 through 09/02/2025, with listed gross proceeds. The filing includes the required certification that the seller is unaware of undisclosed material adverse information at the time of the notice.
Corcept Therapeutics Incorporated reported that board member Gillian Cannon, Ph.D. has resigned from its Board of Directors, effective October 10, 2025. The company states that Dr. Cannon did not resign because of any disagreement regarding its operations, financial statements, policies or practices, indicating this is a non-controversial transition.
Corcept has entered into a Consulting Services Agreement with Dr. Cannon, effective as of her resignation date, under which she will provide consulting services to the Board until the company’s 2026 stockholder meeting. As compensation, she will receive a cash fee of $5,708.33 per month, and her previously granted, outstanding stock options will continue to vest on their original schedules during the consulting term.
Corcept Therapeutics (CORT) CEO and Director Joseph K. Belanoff reported insider stock sales on October 1, 2025 executed under a Rule 10b5-1 trading plan adopted on November 26, 2024.
Sales were reported in three tranches of 5,616, 31,190, and 3,194 common shares at weighted average prices of $84.2895, $85.164, and $85.6662, respectively. The filing notes price ranges for each tranche and that detailed breakdowns are available from the issuer upon request.
Following these transactions, indirect holdings stood at 2,781,370 shares in the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02, over which the reporting person has voting power and disclaims beneficial ownership except to the extent of his pecuniary interest.
Corcept Therapeutics (CORT) insider transaction: On 10/01/2025, an officer exercised 5,000 stock options at an exercise price of $13.56 per share and acquired 5,000 common shares. The same day, the officer sold a total of 5,000 shares in three trades executed under a Rule 10b5-1 plan adopted on August 30, 2024: 927 shares at $83.7111, 3,473 shares at $84.9217, and 600 shares at $85.3875.
Following these transactions, the officer beneficially owned 10,277 common shares. Footnotes state this figure includes unvested restricted stock awards granted on December 2, 2024; March 3, 2025; June 2, 2025; and September 2, 2025, which vest one year from their grant dates if conditions are met. The officer also held 21,571 derivative securities (stock options) after the reported activity, with the exercised option series expiring on 02/07/2030.
Corcept Therapeutics (CORT) insider activity: President Sean Maduck reported option exercises and open‑market sales on 10/01/2025 under a Rule 10b5‑1 plan. He exercised 1,986 stock options at $5.05 and 18,014 at $8.27, then sold 959 shares at a weighted average price of $83.7344, 16,394 at $85.0562, and 2,647 at $85.5758.
Following these transactions, direct holdings were 7,904 shares. Indirect holdings were 59,717 shares held by the Sean and Molly Maduck Living Trust, 40,000 by the SNM 2025 Grantor Retained Annuity Trust, and 10,000 by Duckhill Capital, LLC.
In Table II, the $5.05 option was fully exercised with 0 remaining, and 281,986 options at an exercise price of $8.27 remain outstanding, fully exercisable and expiring on 02/10/2027.
Form 144 notice for Corcept Therapeutics, Inc. (CORT) reports a proposed sale of 40,000 common shares acquired by stock option exercise on 07/06/2022. The sale is to be effected through Stifel Nicolaus & Company Inc. on or about 10/01/2025 with an aggregate market value listed as $3,324,400. The filing shows the issuer's outstanding shares at 105,370,000. The seller appears in recent sale history as Joseph Belanoff, who sold 615 shares on 07/17/2025 for $45,318, 40,000 shares on 08/04/2025 for $2,742,006, and 40,000 shares on 09/02/2025 for $2,821,034. The filer certifies no undisclosed material nonpublic information and provides standard signature/representation language.